Genentech’s Gavreto cleared for RET non-small cell lung cancer
The personalised cancer treatment has received conditional approval in the US
Read More
Tag: RET
Lilly launches first of its kind trial for RET fusion-positive NSCLC
Selpercatinib was designed to inhibit native RET signaling as well as anticipated acquired resistance mechanisms
Read More
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
